Study identifier:ME-CV-1301
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A study to evaluate the use of mobile-phone based patient support in patients diagnosed with Myocardial Infarction - SUPPORT
myocardial infarction
N/A
No
-
All
174
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Dec 2014 by AstraZeneca
AstraZeneca
-
The purpose of this study is to evaluate whether the mobile-phone based patient support has an impact on the adherence and persistence of ticagrelor treatment or on lifestyle changes that will have a positive impact on the cardiovascular risk factors.
Location
Location
Uppsala, Sweden
Location
Goteborg, Sweden
Location
Linkoping, Sweden
Location
Varberg, Sweden
Location
Sundsvall, Sweden
Location
Stockholm, Sweden
Location
Vaxjo, Sweden
Location
Jonkoping, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: Active group The software application used on the patients’ smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use. | Device: Mobile-phone based patient support The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients’ own smart phone and used in addition to medical treatment. Other Name: NA Device: e-diary All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients’ smart phones. |
Placebo Comparator: The control group In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back. | Device: e-diary All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients’ smart phones. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.